{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:32:02Z","timestamp":1774470722249,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T00:00:00Z","timestamp":1404777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s11523-014-0327-8","type":"journal-article","created":{"date-parts":[[2014,7,7]],"date-time":"2014-07-07T01:59:03Z","timestamp":1404698343000},"page":"395-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme"],"prefix":"10.1007","volume":"9","author":[{"given":"Joshua","family":"Mansour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Braxton","family":"Fields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Macomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Rixe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,8]]},"reference":[{"issue":"7","key":"327_CR1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/BRS.0b013e3181c11748","volume":"35","author":"TA Birbilis","year":"2010","unstructured":"Birbilis TA, Matis GK, Eleftheriadis SG et al (2010) Spinal metastasis of glioblastoma multiforme. Spine 35(7):264\u2013269","journal-title":"Spine"},{"key":"327_CR2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"1","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 1:97\u2013109","journal-title":"Acta Neuropathol"},{"issue":"2B","key":"327_CR3","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1590\/S0004-282X2003000300027","volume":"61","author":"EL Gasparetto","year":"2003","unstructured":"Gasparetto EL, Warszawiak D, Adam GP et al (2003) Glioblastoma multiforme of the pineal region: case report. Neuro-Psiquitar 61(2B):468\u2013472","journal-title":"Neuro-Psiquitar"},{"key":"327_CR4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3171\/jns.1988.68.5.0689","volume":"68","author":"MSB Edwards","year":"1988","unstructured":"Edwards MSB, Hudgins RJ, Wilson CB et al (1988) Pineal region tumors in children. J Neurosurg 68:689\u2013697","journal-title":"J Neurosurg"},{"key":"327_CR5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van der Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u201396","journal-title":"N Engl J Med"},{"key":"327_CR6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u201366","journal-title":"Lancet Oncol"},{"issue":"9","key":"327_CR7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"A Malstrom","year":"2012","unstructured":"Malstrom A, Gronberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractioned radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomized, phase 3 trial. Lancet Oncol 13(9):916\u2013926","journal-title":"Lancet Oncol"},{"key":"327_CR8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4137\/CMO.S8503","volume":"7","author":"MJ Gil-Gil","year":"2013","unstructured":"Gil-Gil MJ, Mesia C, Rey M, Bruna (2013) Bevacizumab for the treatment of glioblastoma. Clin Med Insights Onc 7:123\u2013135","journal-title":"Clin Med Insights Onc"},{"issue":"30","key":"327_CR9","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722\u20139","journal-title":"J Clin Oncol"},{"key":"327_CR10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam J, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed Glioblastoma. N Engl J Med 370:699\u2013708","journal-title":"N Engl J Med"},{"key":"327_CR11","doi-asserted-by":"crossref","unstructured":"Henriksson R, Bottomley A, Mason W et al (2013) Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 31 Suppl (abstr 2005)","DOI":"10.1200\/jco.2013.31.15_suppl.2005"},{"key":"327_CR12","doi-asserted-by":"crossref","unstructured":"Taal W, Oosterkamp HM, Walenkamp A et al (2013). A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. J Clin Oncol 31, 2013 Suppl (abstr 2001)","DOI":"10.1200\/jco.2013.31.15_suppl.2001"},{"issue":"11","key":"327_CR13","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-oncology working group. J Clin Oncol 28(11):1963\u20131972","journal-title":"J Clin Oncol"},{"key":"327_CR14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-006-9145-x","volume":"79","author":"A Amini","year":"2006","unstructured":"Amini A, Schmidt RH, Salzman KL et al (2006) Glioblastoma multiforme of the pineal region. J Neurooncol 79:307\u201314","journal-title":"J Neurooncol"},{"key":"327_CR15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11060-006-9241-y","volume":"82","author":"MC Chamberlain","year":"2007","unstructured":"Chamberlain MC, Glantz MJ, Chamlmers L et al (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81\u201383","journal-title":"J Neurooncol"},{"key":"327_CR16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1215\/15228517-2008-008","volume":"10","author":"A Brandes","year":"2007","unstructured":"Brandes A, Tosoni A, Spagnolli F et al (2007) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. Neuro-Oncology 10:361\u2013367","journal-title":"Neuro-Oncology"},{"key":"327_CR17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/1471-2407-9-444","volume":"9","author":"JJ Verhoeff","year":"2009","unstructured":"Verhoeff JJ, van Tellingen O, Claes A et al (2009) Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9:444","journal-title":"BMC Cancer"},{"issue":"6","key":"327_CR18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/WCO.0b013e328332363e","volume":"22","author":"D Brandsma","year":"2009","unstructured":"Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22(6):633\u2013638","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"327_CR19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11910-011-0184-0","volume":"11","author":"W Wick","year":"2011","unstructured":"Wick W, Wick A, Weiler M, Weller M (2011) Patterns of progression in malignant glioma following anti-VEGF therapy; perceptions and evidence. Curr Neurol Neurosci Rep 11(3):305\u2013312","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"327_CR20","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","volume":"79","author":"VA Levin","year":"2011","unstructured":"Levin VA, Bidaut L, Hou P et al (2011) Randomized double-blind placebo-controlled trial of bevaczumab for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487\u201395","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"327_CR21","author":"DR Johnson","year":"2013","unstructured":"Johnson DR, Leeper HE, Uhm JH (2013) Glioblastoma survival in the Unites States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis. Cancer. doi: 10.1002\/cncr.28259","journal-title":"Cancer"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-014-0327-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-014-0327-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-014-0327-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T01:15:09Z","timestamp":1598058909000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-014-0327-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["327"],"URL":"https:\/\/doi.org\/10.1007\/s11523-014-0327-8","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,8]]}}}